Currently, the majority of molecules targeted by therapeutic ligands are cellular proteins, such as human epidermal growth factor receptor 2, which is used for the targeted therapy of HER2-positive breast cancer (4, 5), and folate receptor, which is used for the treatment of folate receptor–overexpressing cancers (6, 7, 8). The gene discussed is ERBB2; the disease is breast carcinoma.